Philux Global Group Inc. (PHIL)

Ligand Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Revenue	-	0.01	0.03	0.03	0.06	0.01
Revenue Growth (YoY)	-	-80.00%	-16.67%	-50.82%	386.79%	-
Gross Profit	-	0.01	0.03	0.03	0.06	0.01
Selling, General & Admin	0.16	0.39	0.56	15.91	0.91	1.87
Operating Expenses	0.16	0.39	0.56	15.91	0.91	1.87
Operating Income	-0.16	-0.39	-0.54	-15.88	-0.85	-1.86
Interest Expense	-0.17	-0.4	-0.93	-1.59	-0.37	-0.3
Other Non Operating Income (Expenses)	-3.99	-7.41	-4.14	-3.68	-5.33	0.84
EBT Excluding Unusual Items	-4.31	-8.2	-5.61	-21.15	-6.55	-1.32
Pretax Income	-4.31	-8.2	-5.61	-21.15	-6.55	-1.32
Net Income	-4.31	-8.2	-5.61	-21.15	-6.55	-1.32
Net Income to Common	-4.31	-8.2	-5.61	-21.15	-6.55	-1.32
Shares Outstanding (Basic)	44,888	44,127	34,456	28,449	17,386	13,152
Shares Outstanding (Diluted)	44,888	44,127	34,456	28,449	17,386	13,152
Shares Change (YoY)	6.97%	28.07%	21.12%	63.63%	32.19%	367.55%
EPS (Basic)	-0.00	-0.00	-0.00	-0.00	-0.00	-0.00
EPS (Diluted)	-0.00	-0.00	-0.00	-0.00	-0.00	-0.00
Free Cash Flow	-0.9	-1.97	-1.57	-1.55	-0.08	-0.72
Gross Margin	-	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-	-7743.68%	-2143.10%	-52937.59%	-1397.73%	-14852.82%
Profit Margin	-	-163907.60%	-22436.58%	-70514.81%	-10742.92%	-10548.28%
Free Cash Flow Margin	-	-39355.00%	-6289.60%	-5151.90%	-130.24%	-5746.75%
EBIT	-0.16	-0.39	-0.54	-15.88	-0.85	-1.86
Revenue as Reported	-	0.01	0.03	0.03	0.06	0.01
Advertising Expenses	-	-	0	0.01	-	0.05

Updated Feb 19, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.